Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Vaccination on the HIV Latent Reservoir
NCT05004038Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bcg vaccine in human immunodeficiency virus infection (HIV), sponsored by University of Zurich. Started Jan 2022; status: completed.
02
Drugs
bcg vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05004038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004038.